GlobeNewswire by notified

Zealand Pharma Provides Update on Silicon Valley Bank Closure

Share

Company announcement – No. 6 / 2023

Zealand Pharma Provides Update on Silicon Valley Bank Closure

  • Update to company announcement No.5 following joint statement by U.S. Treasury, Federal Reserve, and FDIC: Depositors at SVB will have access to all of their money starting Monday, March 13
  • Zealand now expects to recover all of its deposits held at SVB, Monday March 13

Copenhagen, Denmark March 13, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today issued the following update to its March 12, 2023 statement regarding the closure of Silicon Valley Bank (SVB) (company announcement 5/2023):

On March 12, 2023, the U.S. Secretary of the Treasury Janet L. Yellen, U.S. Federal Reserve Board Chair Jerome H. Powell, and Federal Deposit Insurance Corporation (FDIC) Chairman Martin J. Gruenberg, issued a statement announcing that after receiving a recommendation from the boards of the FDIC and the Federal Reserve, and consulting with U.S. President Biden, Secretary Yellen approved actions enabling the FDIC to complete its resolution of SVB in a manner that fully protects all depositors. Depositors will have access to all of their money starting Monday, March 13.

On March 10, 2023, the California Department of Financial Protection and Innovation had closed SVB and appointed the FDIC as receiver.

Zealand has approximately DKK 162.6 million in cash deposits held at SVB as of March 10, 2023, which represents approximately 15% of its total cash, cash equivalents and marketable securities on that date. As of March 10, 2023, Zealand had cash, cash equivalents and marketable securities totaling DKK 1,071.4 million (including deposits at SVB). Zealand expects to recover all of its deposits held at SVB, Monday, March 13. This includes both insured and uninsured deposits.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with several pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.

Contacts:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Heineken Holding N.V. Annual General Meeting of Shareholders adopts all proposals25.4.2024 18:31:00 CEST | Press release

Amsterdam, 25 April 2024 - Heineken Holding N.V. announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The most important resolutions and announcements are listed below. Dividend The Board of Directors announced the distribution of a dividend for the year 2023 of EUR 1.73 per share. As an interim dividend of EUR 0.69 was paid on 10 August 2023, the final dividend of EUR 1.04 per share will be made payable on 7 May 2024. Heineken Holding N.V. shares will be quoted ex-dividend on 29 April 2024. Reappointment of Mr J.F.M.L. van Boxmeer as non-executive member of the Board of Directors The AGM reappointed Mr J.F.M.L. van Boxmeer as non-executive member of the Board of Directors for a four-year term. Appointment of External Auditor The AGM appointed KPMG Accountants N.V. as external auditor for the financial year 2025. The voting results per agenda item of the AGM of Heineken Holding N.V. of 25 April 2024 can be found on th

Heineken N.V. Annual General Meeting adopts all proposals25.4.2024 18:30:00 CEST | Press release

Amsterdam, 25 April 2024 - Heineken N.V. (HEINEKEN) announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The most important resolutions are listed below. Re-appointment of Executive Board Member The AGM re-appointed Dolf van den Brink as member of the Executive Board for a period of four years, until the end of the AGM to be held in 2028. Dividend The AGM adopted the dividend proposal for the year 2023 of EUR 1.73 per share. As an interim dividend of EUR 0.69 was paid on 10 August 2023, the final dividend of EUR 1.04 per share will be made payable on 7 May 2024. Heineken N.V. shares will be quoted ex-dividend on 29 April 2024. Re-appointment of Supervisory Board Member The AGM re-appointed Jean-Marc Huët as member of the Supervisory Board for a two-year term. Re-appointment of Supervisory Board Member The AGM re-appointed Pamela Mars Wright as member of the Supervisory Board for a two-year term. Appointment of Supervi

Havila Kystruten AS: Integrated Annual Report for 202325.4.2024 18:04:39 CEST | Press release

The board of directors of Havila Kystruten AS has today approved the financial statements and annual report for 2023, which integrates financial and sustainability reporting. The report is attached in PDF format along with a visual presentation summarizing the year and highlighting the company's fundamental focus on the environment and sustainability. The annual financial statements have been adjusted compared to the preliminary and unaudited result for 2023, which was presented on February 28, 2024. There has been a write-down of the inventory value by NOK 11.2 million, with corresponding effects on the income statement and balance sheet. Further information is available in note 15 of the consolidated financial statements. Contacts: Chief Executive Officer Bent Martini, +47 905 99 650 Chief Financial Officer Aleksander Røynesdal, +47 413 18 114 Attachments HKY_Integrated Annual Report 2023HKY_Integrated Annual Report Presentation 2023HKY_Integrert arsrapport 2023

Havila Kystruten AS: Integrert årsrapport for 202325.4.2024 18:04:39 CEST | Pressemelding

Styret i Havila Kystruten AS har i dag godkjent regnskap og årsrapport for 2023, som integrerer finansiell- og bærekraftsrapportering. Rapporten er vedlagt i PDF sammen med en visuell presentasjon som oppsummerer året og fremhever selskapets grunnleggende fokus på miljø og bærekraft. Årsregnskapet er justert i forhold til det foreløpige og ureviderte resultatet for 2023, som ble presentert den 28. februar 2024. Det er gjort en nedskrivning på verdien av varelageret med MNOK 11.2, med tilhørende effekt på resultatet og balansen. Ytterligere informasjon finnes i note 15 i konsernregnskapet. Kontakter: Administrerende direktør Bent Martini, +47 905 99 650 Finansdirektør Aleksander Røynesdal, + 47 413 18 114

Sword Group: Results for the First Quarter of 202425.4.2024 18:00:00 CEST | Press release

Consolidated Revenue: €75.8m (i) Organic Growth: +16.8% (i) EBITDA Margin: 12.0% (i) on a like-for-like basis and at constant exchange rates (excluding AAA) KEY FIGURES The consolidated revenue for the first quarter of 2024 is €75.8m, up 16.8% at constant scope and exchange rates. Profitability (EBITDA margin) is 12.0% or €9.1m. Q1 2024 ACCOUNTS Q1 | non audited figures€m20242023 (iI)Organic Growth (i)Revenue75.872.0+16.8%EBITDA9.18.6-EBITDA Margin12.0%12.0%- (i) on a like-for-like basis and at constant exchange rates (excluding AAA) (ii) includes AAA’s 2023 revenue. AAA was deconsolidated on 01/06/2023. ANALYSIS The comparison of revenue for the first quarter 2023 and the first quarter 2024 must take into account the fact that in the first quarter 2023 we were still consolidating AAA, which was sold and therefore deconsolidated on 1 June 2023. If we analyse this growth on a like-for-like basis, it is higher than the budgeted 15%. In Terms of profitability, we remain at our ‘normative’

HiddenA line styled icon from Orion Icon Library.Eye